Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Stomach Neoplasms × derazantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 4 Liver Neoplasms 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 2 Acrocephalosyndactylia 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

Oxaliplatin 271 Capecitabine 190 Fluorouracil 167 Cisplatin 153 Docetaxel 125 S 1 (combination) 123 Paclitaxel 117 Leucovorin 110 Irinotecan 102 pembrolizumab 91 Trastuzumab 64 apatinib 55 Nivolumab 53 Drug Therapy 48 Surgical Procedures, Operative 41 sintilimab 39 Radiotherapy 39 Ramucirumab 36 Bevacizumab 34 Hyperthermic Intraperitoneal Chemotherapy 31 Carboplatin 31 tislelizumab 30 Epirubicin 29 titanium silicide 27 Gastrectomy 26 XELOX 24 Cyclophosphamide 24 Tegafur 22 camrelizumab 20 Folfox protocol 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04604132 2024-04-04

FIDES-03

Basilea Pharmaceutica

Phase 1/2 Terminated

47 enrolled 22 charts

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡